J&J Medical Connect
BALVERSA®

(erdafitinib)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

BALVERSA - Skin Disorders

Last Updated: 11/16/2026

SUMMARY

  • THOR (BLC3001/NCT03390504) is an ongoing, phase 3, randomized, open-label, multicenter study evaluating the efficacy and safety of BALVERSA vs chemotherapy (docetaxel or vinflunine) or pembrolizumab in patients with metastatic or unresectable urothelial carcinoma (UC) and select FGFR alterations who had disease progression during or after 1 or 2 prior lines of therapy.1,2
    • In the interim analysis of cohort 1 (n=266), treatment-related skin adverse events (AEs) of any grade reported in the safety population included palmar-plantar erythrodysesthesia syndrome (30.4%), alopecia (23.7%), and dry skin (22.2%).3
    • In the fully enrolled cohort 1 analysis (safety population: BALVERSA n=142; chemotherapy n=117), the safety profiles of BALVERSA and chemotherapy were consistent with the primary analysis.4
      • All grade and grade ≥3 treatment-related skin disorders were reported in 80 (56.3%) and 17 (12.0%) patients in the BALVERSA arm vs 17 (14.5%) and 0 patients in the chemotherapy arm, respectively.5
  • BLC2001 (NCT02365597) is an ongoing, phase 2, open-label, multicenter study of BALVERSA in patients with locally advanced and unresectable or metastatic UC and prespecified FGFR alterations (FGFR3 mutation or FGFR2/3 fusion).6,7
    • In the final analysis (n=101), the safety profile remained similar to that in the primary analysis, with no new safety signals reported with a longer follow-up. The most common treatment-related skin AEs, of any grade, included dry skin (33.7%), alopecia (29.7%), and palmar-plantar erythrodysesthesia syndrome (24.8%). Grade 3 palmar-plantar erythrodysesthesia syndrome was reported (5%), and there were no reports of grade 3 dry skin or alopecia.6
  • Follow dose modification guidelines for adverse reactions within product labeling. For the medical management of dry skin during the THOR study, refer to Table: Guidelines for the Management of Dry Skin in the THOR Study.

CLINICAL DATA

To provide the most relevant information, the summary below is limited to information from the pivotal phase 3 (THOR/BLC3001; cohort 1) and phase 2 (BLC2001) studies in patients with locally advanced or metastatic UC and selected FGFR alterations.

Phase 3 Study in Patients With Locally Advanced or Metastatic UC (THOR/BLC3001)

Interim Cohort 1 Analysis

THOR is an ongoing phase 3, randomized, open-label, multicenter study evaluating the efficacy and safety of BALVERSA vs chemotherapy (docetaxel or vinflunine) or pembrolizumab in patients with metastatic or unresectable UC and selected FGFR alterations who had disease progression during or after 1 or 2 prior lines of therapy. The primary endpoint is overall survival.1

  • In cohort 1, 266 patients were randomized 1:1 to receive an uptitration regimen of BALVERSA 8 mg orally once daily or chemotherapy (docetaxel 75 mg/m2 intravenous [IV] every 3 weeks [Q3W] or vinflunine 320 mg/m2 IV Q3W).1
  • Interim results from cohort 1 (n=266) were presented after a median follow-up of 15.9 months. The safety profiles were consistent with the known safety profiles of BALVERSA and chemotherapy.1
  • Median duration of exposure was longer for the BALVERSA group at 4.8 months (range, 0.2-38.2) compared to the chemotherapy group at 1.4 months (range, 0.03-27.0).1
  • Among AEs of any cause in the safety population, palmar-plantar erythrodysesthesia syndrome occurred in 41 (30.4%) patients in the BALVERSA group and 1 (0.9%) patient in the chemotherapy group. Alopecia occurred in 34 (25.2%) and 27 (24.1%) and dry skin occurred in 31 (23.0%) and 5 (4.5%) patients in the BALVERSA and chemotherapy groups, respectively.1
  • Grade 3/4 AEs of interest based on the known safety profile of BALVERSA included skin disorders which occurred in 11.9% patients in the BALVERSA group.1 Skin disorders included blister, dry skin, erythema, hyperkeratosis, palmar erythema, palmar-plantar erythrodysesthesia syndrome, plantar erythema, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, skin atrophy, skin exfoliation, skin fissures, skin lesion, skin ulcer, toxic skin eruption, and xeroderma.3
  • Grade 3/4 TRAEs occurred in 45.9% patients in the BALVERSA group and 46.4% patients in the chemotherapy group.1
    • The most common grade ≥3 TRAE in the BALVERSA group was palmar-plantar erythrodysesthesia syndrome (9.6%).
  • AEs of any cause led to treatment discontinuation in 19 (14.1%) patients in the BALVERSA group and 20 (17.9%) patients in the chemotherapy group. Dry skin led to treatment discontinuation in 1 (0.7%) patient in the BALVERSA arm.3

THOR Cohort 1 Safety Population: Treatment-Related Skin AEs3
AE, n (%)
BALVERSA (n=135)
Chemotherapy (n=112)
Any Grade
Grade
1

Grade
2

Grade ≥3
Any Grade
Grade
1

Grade
2

Grade ≥3
Palmar-plantar erythrodysesthesia syndrome
41
(30.4)

6
(4.4)

22
(16.3)

13
(9.6)

1
(0.9)

0
1
(0.9)

0
Alopecia
32
(23.7)

27
(20.0)

4
(3.0)

1
(0.7)

24
(21.4)

15
(13.4)

9
(8.0)

0
Dry skin
30
(22.2)

22
(16.3)

6
(4.4)

2
(1.5)

4
(3.6)

3
(2.7)

1
(0.9)

0
Abbreviations: AE, adverse event.

Fully Enrolled Cohort 1 Analysis

At the end of data collection in the fully enrolled cohort 1, with a median OS follow-up of 21 months for BALVERSA and 18 months for chemotherapy, 142 patients received BALVERSA 8 mg once daily and 117 received chemotherapy. The median treatment exposure durations for BALVERSA and chemotherapy were 4.9 months (range, 0-42) and 1.4 months (range, 0-31), respectively.4


Fully Enrolled THOR Cohort 1: Incidence of Treatment-Emergent Skin Disorders5
AEs, n (%)a
BALVERSA (n=142)
Chemotherapy (n=117)
Any Grade
Grade ≥3
Any Grade
Grade ≥3
Palmar-plantar erythrodysesthesia syndrome
44 (31.0)
14 (9.9)
2 (1.7)
0
Alopecia
37 (26.1)
1 (0.7)
28 (23.9)
0
Dry skin
34 (23.9)
2 (1.4)
5 (4.3)
0
Abbreviations: AE, adverse event.
aTreatment-emergent AEs by preferred term are listed if events of any grade occurred in ≥15% of patients in either treatment group.


Fully Enrolled THOR Cohort 1 Safety Population: Incidence of Treatment-Related Skin Disorders5
AEs, n (%)a
BALVERSA (n=142)
Chemotherapy (n=117)
Any Grade
Grade ≥3
Any Grade
Grade ≥3
Palmar-plantar erythrodysesthesia syndrome
44 (31.0)
14 (9.9)
2 (1.7)
0
Alopecia
35 (24.6)
1 (0.7)
25 (21.4)
0
Dry skin
33 (23.2)
2 (1.4)
4 (3.4)
0
AEs of interest
   Skin disordersb
80 (56.3)
17 (12.0)
17 (14.5)
0
Abbreviations: AE, adverse event.
aTRAEs by preferred term are listed if events of any grade occurred in ≥15% of patients in either treatment group.bSkin disorders: Blister, dry skin, erythema, hyperkeratosis, palmar erythema, palmar-plantar erythrodysesthesia syndrome, plantar erythema, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, skin atrophy, skin exfoliation, skin fissures, skin lesion, skin ulcer, toxic skin eruption, and xeroderma.


Fully Enrolled THOR Cohort 1 Safety Population: Incidence of Treatment-Emergent Skin Disorder Leading to Dose Reduction5
AEs, n (%)a
BALVERSAb (n=142)
Chemotherapy (n=117)
Palmar-plantar erythrodysesthesia syndrome
13 (9.2)
1 (0.9)
Abbreviation: AE, adverse event.
aTreatment-emergent AEs leading to dose reduction by preferred term that were reported in ≥2% of patients in either treatment group.bDose reductions in the BALVERSA group are defined as any reduction to below the 8 mg dose (de-escalation from 9 mg to 8 mg are not included).

  • There were no reports of skin disorders leading to treatment discontinuation.5

Phase 2 Study in Patients With Locally Advanced or Metastatic UC (BLC2001)

Final Analysis

BLC2001 is an ongoing, phase 2, open-label, multicenter study evaluating the use of BALVERSA in patients with locally advanced and unresectable or metastatic UC who had prespecified FGFR alterations (FGFR3 mutation or FGFR2/3 fusion) and disease progression during or following ≥1 line of prior systemic chemotherapy or within 12 months of neoadjuvant or adjuvant chemotherapy or were chemotherapy-naïve due to cisplatin ineligibility. Patients had tumor tissues with one of the following FGFR3 mutations: R248C, S249C, G370C, Y373C or one of the following FGFR fusions: FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR2-BICC1, FGFR2-CASP7.7,8

  • In the final analysis, after a median 24 month follow-up for efficacy (interquartile range [IQR], 22.7-26.6) and median treatment duration of 5.4 months (IQR, 2.8-9), 101 patients were treated with an uptitration regimen of BALVERSA 8 mg once daily (2 patients were enrolled after the clinical cutoff date for the primary analysis). Overall, 60 patients received BALVERSA 8 mg daily and 41 were uptitrated to BALVERSA 9 mg daily.6,9
  • The safety profile of BALVERSA remained consistent with that of the primary analysis.6
  • The most common treatment-related skin events (grade 1-3) are presented in the Table: BLC2001: Most Common Treatment-Related Skin AEs. Grade 4/5 events of dry skin, alopecia, or palmar-plantar erythrodysesthesia syndrome were not reported in patients treated with BALVERSA.9
  • Treatment-related skin AEs that led to treatment discontinuation were palmar-plantar erythrodysesthesia syndrome (n=2) and skin ulcer (n=1).9
  • A total of 55 (54.5%) patients treated with BALVERSA 8 mg daily reported treatment-emergent skin AEs.9
    • The most frequently occurring treatment-emergent skin AEs were dry skin (33.7%), palmar-plantar erythrodysesthesia syndrome (24.8%), and erythema (7.9%).

BLC2001: Most Common Treatment-Related Skin AEs9
AE, n (%)
BALVERSA 8 mg Daily UpT (N=101)
Any Grade
Grade 1
Grade 2
Grade 3
Dry skin
34 (33.7)
25 (24.8)
9 (8.9)
0
Alopecia
30 (29.7)
23 (22.8)
7 (6.9)
0
Palmar-plantar erythrodysesthesia syndrome
25 (24.8)
5 (5.0)
15 (14.9)
5 (5.0)
Abbreviations: AE, adverse event; UpT, potential for uptitration to 9 mg daily.

BLC2001: Treatment-Emergent Skin Adverse Events10
Adverse Event
Data Value
Developed skin event, n/N with ≥1 TEAE (%)
55/101 (55)
Median (range) time to onset of skin event, days
42 (1-268)
Had dose modification for skin event, n/N with skin event (%)
   Dose reduction
11/55 (20)
   Dose interruption
13/55 (24)
   Discontinuation
3/55 (5)
Received treatment for skin event, na/N with skin event (%)
31/55 (56)
Most common skin event: dry skin
   Median (range) time treatment was withheld for dry skin, days
3 (3-3)
   Resolution of ≥1 dry skin event by data cutoff, nb/N with dry skin (%)
19/34 (56)
   Median (range) time to resolution of dry skin, days
42 (8-334)
Abbreviations: TEAE, treatment-emergent adverse event.
aAmong the 31 patients receiving concomitant medications, the most common therapies were emollients and protectives (45%) and systemic corticosteroids (29%).
bAmong patients with dry skin, ≥1 event resolved in 2 of 2 patients with dose reduction and in 1 of 1 with dose interruption (none had dry skin leading to treatment discontinuation).

GUIDELINES FOR the MANAGEMENT OF DRY SKIN AND SKIN TOXIcity IN THE thor AND BLC2001 STUDIES

Guidelines and interventions that investigators were instructed to perform to manage dry skin (Table: Guidelines for the Management of Dry Skin in the THOR and BLC2001 Studies) and skin toxicity are summarized in this section. These are not recommendations. Interventions should be based on patient presentation and the clinical judgment of the treating physician for dry skin and skin toxicity.8,11

  • General prophylaxis8,11:
    • Avoid unnecessary exposure to sunlight and excessive use of soap.
    • Avoid bathing in excess; use tepid rather than hot water.
    • Use moisturizers regularly; apply thick, alcohol-free and oil-in-water based emollient cream on exposed and dry areas of the body.
    • Avoid perfumed products, bubble bath, perfumed soaps, and take breaks from shaving.
    • Use broad spectrum sunscreen with a skin protection factor (SPF) ≥15.
    • Wear cotton clothes next to skin rather than wool, synthetic fibers, or rough clothing.
    • Use occlusive alcohol-free emollient creams (jar or tub) for treatment of mild/moderate xerosis.
    • For scaly areas, use exfoliants (ammonium lactate 12% or lactic acid cream 12%).

Guidelines for the Management of Dry Skin in the THOR and BLC2001 Studies8,11
Grade and Definition
Drug Management
Medical Management
Grade 1: Dry skin covering less than 10% BSA and no associated erythema or pruritus
Continue BALVERSA at current dose.
  • Use fragrance-free moisturizing cream or ointment BID over entire body.
  • Use ammonium lactate 12% cream or salicylic acid 6% cream BID over dry/scaly/hyperkeratotic areas such as palms and soles.
Grade 2: Dry skin covering 10 to 30% BSA and associated with erythema or pruritis with limited IADL
Continue BALVERSA at current dose.
  • Use fragrance-free moisturizing cream or ointment BID over entire body.
  • Use ammonium lactate 12% cream or salicylic acid 6% cream BID over dry/scaly/hyperkeratotic areas such as palms and soles.
  • Use zinc oxide 13-40% at night for areas with fissures.
Grade 3: Dry skin covering >30% BSA and associated with pruritis; limiting self-care ADL
  • Hold BALVERSA (for up to 28 days) with weekly reassessments of clinical condition.
  • When resolves to ≤grade 1 or baseline, restart at 1 dose level below in consultation with medical monitor.
Use topical steroid ointment or creama BID and zinc oxide 13% to 40% at night for areas with fissures.
Grade 4: Dry skin with life-threatening consequences, urgent intervention indicated
Discontinue BALVERSA.
Evaluation and therapy as clinically indicated.
Abbreviations: ADL, activities of daily living; BID, twice daily; BSA, body surface area; IADL, instrumental activities of daily living.
aTopical steroid ointments: clobetasol 0.05%, betamethasone 0.05%, fluocinonide 0.05%.

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 29 October 2026. Pivotal study data of BALVERSA monotherapy for the treatment of advanced and metastatic UC are included in this response.

References

1 Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961-1971.  
2 Janssen Research & Development, LLC. A phase 3 study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in subjects with advanced urothelial cancer and selected FGFR gene aberrations. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2026 October 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03390504 NLM Identifier: NCT03390504.  
3 Loriot Y, Matsubara N, Park SH, et al. Supplement for: Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961-1971.  
4 Loriot Y, Matsubara N, Park SH, et al. Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma. ESMO Open. 2026;11(10):108583.  
5 Loriot Y, Matsubara N, Park SH, et al. Supplement to: Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma. ESMO Open. 2026;11(10):108583.  
6 Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23(2):248-258.  
7 Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.  
8 Loriot Y, Necchi A, Park SH, et al. Protocol for: Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.  
9 Siefker-Radtke AO, Necchi A, Park SH, et al. Supplement for: Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol. 2022;23(2):248-258.  
10 Siefker-Radtke AO, Necchi A, Park SH, et al. Management of fibroblast growth factor receptor inhibitor treatment-emergent adverse events of interest in patients with locally advanced or metastatic urothelial carcinoma. Poster presented at: American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium; February 11-13, 2021; Virtual.  
11 Loriot Y, Matsubara N, Park SH, et al. Protocol for: Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961-1971.   

Would you like to clear and leave your conversation? Message history will be lost.